Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

2026 BIO International Convention In-Depth Analysis Report

The 2026 BIO International Convention, held June 22-25, 2026 at the San Diego Convention Center, marked a pivotal moment for the biotechnology industry. With nearly 20,000 attendees from over 76 countries (43% international), the event showcased a resurgent biotech sector characterized by record-breaking deal activity, accelerated AI adoption, and renewed investor confidence. The convention's theme, "Driven by Purpose," underscored the industry's commitment to transforming scientific breakthroughs into life-changing therapies. Notable highlights included a landmark $2.5 billion AI-powered drug discovery collaboration, over $100 billion in M&A activity, approximately 70,000 partnering meetings, and transformative regulatory updates from the FDA and EMA.

Read →

EHA 2026 | ATG vs PTCY GVHD Prophylaxis Clinical Outcome Analysis Report

Abstract: EHA-7202 Short: LB5009 The question of whether post-transplant cyclophosphamide (PTCy) should replace anti-thymocyte globulin (ATG/ATLG) as the standard GVHD prophylaxis backbone in HLA-compatible 10/10 matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) has now been directly addressed by a large, prospective randomized controlled trial presented at EHA 2026 by Prof. Johannes Schetelig (Dresden, Germany) and co-investigators including Matthias Stelljes. The trial — designated the GRAPPA study — concludes that ATG-based prophylaxis retains its standard-of-care position in this specific setting, with PTCy failing to demonstrate superiority on the primary composite endpoint. This finding is contextualized against a backdrop of registry data, meta-analyses, and prior Phase 2/3 evidence that had generated significant debate about PTCy's potential to displace ATG in the 10/10 MUD context.

Read →

EHA 2026 | BRUIN CLL-322: Clinical Outcome Analysis Report

Abstract: EHA-7224 Short: LB5001 BRUIN CLL-322 (NCT04965493) is the first randomized Phase 3 trial to evaluate a non-covalent BTK inhibitor–based triplet regimen in previously treated CLL/SLL. With a data cutoff of February 2, 2026, and results presented at EHA 2026, the trial demonstrated that fixed-duration pirtobrutinib + venetoclax–rituximab (PVR) significantly improved progression-free survival over venetoclax–rituximab (VenR) alone, meeting its primary endpoint across all key subgroups. Overall survival data were not yet mature but trended in favor of PVR. This represents Lilly's fourth Phase 3 CLL win for pirtobrutinib (Jaypirca®) and positions PVR as a potential new standard of care in the relapsed/refractory setting.

Read →

EHA 2026 | Gilteritinib vs Midostaurin FLT3 AML Clinical Outcome Analysis Report

Abstract: EHA-7247 Short: LB5005 The PASHA trial is the first randomized Phase 3 head-to-head comparison of a second-generation FLT3 inhibitor (gilteritinib) against the established first-generation standard (midostaurin), both combined with intensive induction/consolidation chemotherapy and followed by one-year maintenance, in patients with newly diagnosed FLT3-mutated AML eligible for intensive therapy. Results were presented as a Late-Breaking Abstract at EHA 2026 (Stockholm, June 2026) by Dr. Marc Raaijmakers on behalf of the HOVON-AMLSG consortium.

Read →

EHA 2026 | SUCCESSOR-2 Phase 3 Readout: MeziKd Demonstrates Clinical Outcome Profile versus Kd in RRMM

Abstract: EHA-7170 Short: LB5004 The Phase 3 SUCCESSOR-2 trial (NCT05552976) demonstrated that adding mezigdomide (a next-generation CELMoD/molecular glue degrader) to the established carfilzomib + dexamethasone (Kd) backbone produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). The trial met its primary endpoint, with MeziKd showing superior PFS and higher response rates versus Kd alone. The overall evaluation was Positive, representing a landmark Phase 3 validation of the CELMoD drug class in combination with a proteasome inhibitor.

Read →

2026 EHA Global Hematology Congress In-Depth Analysis Report

The 31st EHA Congress in Stockholm marks a paradigm shift across hematologic malignancies. Five forces dominate: bispecific antibodies become new standards, menin inhibitors break through in AML, non-covalent BTK + next-gen BCL2 reshape CLL, MRD-driven fixed-duration strategies prevail, and CAR-T enters multi-generation upgrades. MonumenTAL-3 delivers a 72% PFS risk reduction (triplet) and 67% (doublet) in RRMM, while KOMET-007 demonstrates 90–96% CRc and >80% MRD-negativity in NPM1m/KMT2A-r AML — the field is now defined by deep, durable, MRD-guided remissions. Janssen consolidates MM leadership (teclistamab + talquetamab dual track); BeiGene's zanubrutinib + sonrotoclax all-oral combo challenges venetoclax+obinutuzumab in frontline CLL.

Read →

May 2025 Patent Highlights

1,Vertex continues to focus on the field of pain 2,Monte Rosa's CDK2 molecular glue degraders 3,Eisbach's ALC1 inhibitor 4,Roche's tri-complex inhibitors 5,Eli Lilly’s CRHR2 peptide agonists 6,LP(a) inhibitor from CSPC is better？

Read →

JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics

This report features four highly representative and innovative therapeutics recently profiled in the JMC Annotation column (submitted before December 2024 and with no clinical failure reported to date). The selection spans a diverse range of modalities, including covalent inhibitors, receptor-selective agonists, and CNS-penetrant compounds. The drugs are being developed by leading pharmaceutical and biotech companies such as Chiesi Farmaceutici S.p.A., Galapagos, Scorpion Therapeutics, and AstraZeneca.Through a systematic examination of the R&D paths of these compounds, this report aims to uncover their therapeutic potential, while also offering insight into their commercial prospects and developmental challenges.

Read →

Global Potential Targets and FIC Product Research Report (Q4 2024)

1，A comprehensive review was conducted of the 55 new drugs approved by the FDA in 2023, including 20 First-in-Class (FIC) therapies. Additionally, an analysis was performed on 8 promising FIC single-target agents and 10 FIC dual-target agents with significant potential for the first three quarters of 2024. 2，This report provides a comprehensive overview of the promising First-in-Class (FIC) single-target and dual-target agents anticipated for the fourth quarter of 2024. It includes detailed analyses of their mechanisms of action, current research and development progress, and potential clinical applications. 3，Depth Analysis of Potential Single-target FIC Varieties: This section provides an in-depth examination of the following single-target First-in-Class (FIC) agents: LTCC modulators, M2R allosteric modulators, S2R modulators, BRD4 BD2 inhibitors, PKMYT1 inhibitors, TAK1 inhibitors, NLRP3 inhibitors, and oral KRAS G12D inhibitors. The analysis covers their mechanisms of action, current research progress, and patent application status. 4, In-depth Analysis of Potential Dual-Target FIC Varieties: This section provides a comprehensive examination of the FXR-LIFR dual-target regulators and ROCK-HDAC dual-target inhibitors, both of which are First-in-Class (FIC) compounds. The analysis delves into their development potential and patent landscape.

Read →